Gilead Sciences Inc. casts itself as a biopharmaceutical company focused on the discovery, development, and commercialization of medicines for addressing various unmet medical needs. The company came into being as a brainchild of Michael L Riordan in 1987.
Headquartered in Foster California, the company specializes in the development of treatments for HIV Hepatitis B Hepatitis C and Influenza. Its lead products include Descovy and Truvada for the treatment of HIV infection and Harvoni for the treatment of liver diseases.
The company has grown through mergers and acquisitions. Its biggest acquisition to date is the purchase of Pharmasset inc. in a deal that cost it $10.4 billion. Its other notable acquisition is YM Biosciences for $510 million.
Gilead Sciences Inc. went public in 1992 and got listed on the NASDAQ Stock Exchange in an Initial Public Offering that raised $86.25 million.